Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 2/2021

EFFICACY AND SAFETY OF THROMBOPOIETIN RECEPTOR AGONISTS IN MODERN TREATMENT OF IMMUNE THROMBOCYTOPENIA

ANDRADA PARVU 1,2*, OLGA HILDA ORASAN 3, STEFAN VLAD POP 1,4, IULIA ANDREA
ZSOLDOS 1, CRISTINA CATANA 1, IOANA STEFANIA DEAC 1, ANCA SIMONA BOJAN 1,2

1.Haematology Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, 73 21-Decembrie Boulevard, ClujNapoca, Romania
2.Haematology Department, “Prof. Dr. Ion Chiricuţă” Oncological Institute, 73 21-Decembrie Boulevard, Cluj-Napoca, Romania
3.4th Medical Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, 18 Republicii Street, Cluj-Napoca,
Romania
4.Emergency County Hospital, 2 Ravensburg Street, Satu-Mare, Romania

Download Full Article PDF

Immune thrombocytopenia (IT), characterized by isolated platelet decrease and bleeding, could be primary or secondary to infections, autoimmune diseases, drugs. Classical treatments for IT are corticosteroids, immunoglobulins (1st line) and splenectomy, immunosuppression (2nd line), therapies based on decreasing platelets’ destruction. Thrombopoietin receptor agonists (TRA), romiplostim, eltrombopag and avatrombopag, modern drugs used for refractory patients, increase platelets production. The aim of the article is a review of literature based on 59 scientific articles regarding the efficacy and safety of TRA in primary IT. This review is helpful to specialists, given the limited experience with these drugs, approved in 2008 in the United States and in 2009 in Europe. TRA have shown good efficacy, treatment leading to increased platelet counts, decreased haemorrhagic episodes, reduced concomitant medication. TRA were well tolerated, the adverse effects reported were medullary fibrosis, thrombosis, headache, rhinopharyngitis, hepatocitolysis, fatigue.